The Science Hat Podcast - Season 3 Episode 3 - Radiopharm sweet spot: Finding the goldilocks zone

Isotopes have been a big topic of discussion in radiopharmaceuticals. In targeted radiopharmaceutical therapies (TRT), the isotope is just one part of the product, and the TRT market is currently dominated by products utilising beta emitters. The alpha emitters have received a lot of hype, but to date have very limited clinical data, some of which already showing significant safety concerns for patients, and coupled with the current supply chain limitations, alphas still have a long road ahead. Watch season 3 episode 3 below, featuring Clarity’s Executive Chairperson, Dr Alan Taylor, and Healthcare Analyst, Melissa Benson, as they discuss the benefits and limitations of alphas vs betas, the concept of the Goldilocks Zone, the need to focus on products that are safe and efficacious, and implications for cancer patients in need of novel treatment options. Click on the following link to watch previous episodes of the Science Hat podcast and learn more about Clarity’s TCT platforms: https://www.claritypharmaceuticals.com